Mr. Minick is a Venture Partner at the life science venture capital firm ARCH Venture Partners. He previously served as President and CEO of BIND Therapeutics, Inc. (NASDAQ: BIND), a biopharmaceutical company focused on the development of targeted and programmable nanoparticles for cancer therapy. Prior to that, Mr. Minick was a Managing Director of ARCH, and he was previously President and COO of SEQUUS Pharmaceuticals, Inc. (NASDAQ:SEQU), a liposome-based drug development company that was acquired by ALZA Corporation. Earlier in his career, he was an executive at Baxter International, Inc., and Eli Lilly & Company. Mr. Minick currently serves as Chief Executive Officer of StrongHolt; is a member of the board of directors of Soley, Inc., and Chiasma, Inc.; and is a Trustee of Beth Israel Deaconess Medical Center. He received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University, and a B.A. from the University of California, San Diego.